Severe hepatotoxicity associated with the combination of enfuvirtide and tipranavir/ritonavir: Case report [2]

AIDS

Volumn 20, Issue 11, 2006, Pages 1563-

  Jülg, Boris ^a,b   Bogner, J R ^a   Goebel, F D ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; ENFUVIRTIDE; GAMMA GLUTAMYLTRANSFERASE; LAMIVUDINE; RITONAVIR; TIPRANAVIR; ZIDOVUDINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIVER BIOPSY; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SKIN MANIFESTATION; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, MULTIPLE, VIRAL; HEPATITIS, TOXIC; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PYRIDINES; PYRONES;

EID: 33746191208     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000237377.61809.87     Document Type: Letter

References (4)

1. Flexner C, Bate G, Kirkpatrick P. Tipranavir. Nat Rev Drug Discov 2005; 4:955-956.
2. Cahn P, et al. 24-week data from RESIST-2: Phase 3 study of the efficacy and safety of either tipranavir/ritonavir (TPV/r) or an optimized ritonavir (RTV)-boosted standard-of-care (SOC) comparator PI (CPI) in a large randomized multicenter trial in treatment-experienced HIV patients. Abstract: PL 14.3. Seventh International Congress on Drug Therapy in HIV Infection. Glasgow, November 2004 [abstract PL 14.3].
3. Gonzales de Requena D, Calcagno A, Bonora S, Ladetto L, D'Avolio A and Sciandra M. Unexpected drug-drug interactions between tipranavir/ritonavir and enfuvirtide. Thirteenth Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [abstract 579].
4. Hicks et al. RESIST-1: A Phase 3 randomized, controlled, open-label multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in antiretroviral (ARV) experienced patients: 24-week data. 44th Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington DC, October-November 2004 [abstract H-1137a].